|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NFE2L3 |
Gene summary for NFE2L3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NFE2L3 | Gene ID | 9603 |
| Gene name | nuclear factor, erythroid 2 like 3 | |
| Gene Alias | NRF3 | |
| Cytomap | 7p15.2 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q9Y4A8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9603 | NFE2L3 | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.01e-02 | 3.57e-01 | 0.0588 |
| 9603 | NFE2L3 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 6.15e-24 | 7.45e-01 | 0.294 |
| 9603 | NFE2L3 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 1.51e-03 | 8.41e-01 | 0.3487 |
| 9603 | NFE2L3 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.24e-07 | 4.38e-01 | 0.3859 |
| 9603 | NFE2L3 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 3.79e-10 | 3.89e-01 | 0.3005 |
| 9603 | NFE2L3 | A015-C-104 | Human | Colorectum | FAP | 4.02e-02 | -8.51e-02 | -0.1899 |
| 9603 | NFE2L3 | AEH-subject1 | Human | Endometrium | AEH | 8.57e-03 | 1.96e-01 | -0.3059 |
| 9603 | NFE2L3 | AEH-subject3 | Human | Endometrium | AEH | 9.98e-08 | 3.76e-01 | -0.2576 |
| 9603 | NFE2L3 | AEH-subject4 | Human | Endometrium | AEH | 5.33e-12 | 4.55e-01 | -0.2657 |
| 9603 | NFE2L3 | AEH-subject5 | Human | Endometrium | AEH | 2.71e-06 | 2.23e-01 | -0.2953 |
| 9603 | NFE2L3 | EEC-subject1 | Human | Endometrium | EEC | 8.23e-28 | 7.39e-01 | -0.2682 |
| 9603 | NFE2L3 | EEC-subject4 | Human | Endometrium | EEC | 1.46e-08 | 3.27e-01 | -0.2571 |
| 9603 | NFE2L3 | EEC-subject5 | Human | Endometrium | EEC | 3.56e-05 | 2.14e-01 | -0.249 |
| 9603 | NFE2L3 | GSM5276935 | Human | Endometrium | EEC | 3.38e-09 | 2.48e-01 | -0.123 |
| 9603 | NFE2L3 | LZE7T | Human | Esophagus | ESCC | 1.02e-03 | 1.85e-01 | 0.0667 |
| 9603 | NFE2L3 | LZE24T | Human | Esophagus | ESCC | 1.46e-02 | 1.11e-01 | 0.0596 |
| 9603 | NFE2L3 | P2T-E | Human | Esophagus | ESCC | 3.00e-96 | 1.78e+00 | 0.1177 |
| 9603 | NFE2L3 | P4T-E | Human | Esophagus | ESCC | 4.48e-22 | 4.82e-01 | 0.1323 |
| 9603 | NFE2L3 | P5T-E | Human | Esophagus | ESCC | 7.08e-04 | 1.17e-01 | 0.1327 |
| 9603 | NFE2L3 | P9T-E | Human | Esophagus | ESCC | 3.82e-08 | 2.24e-01 | 0.1131 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | CRC |  |
| Stomach | GC |  |
| Stomach | CAG with IM |  |
| Stomach | CSG |  |
| Stomach | CAG |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| NFE2L3 | MAST | Breast | Healthy | CD1E,SPINT1,CLEC10A, etc. | 7.49e-02 |  |
| NFE2L3 | MAST | Breast | IDC | CD1E,SPINT1,CLEC10A, etc. | 1.54e-01 |  |
| NFE2L3 | TREG | Breast | Precancer | CD1E,SPINT1,CLEC10A, etc. | 3.55e-02 |  |
| NFE2L3 | MAST | Breast | Precancer | CD1E,SPINT1,CLEC10A, etc. | 6.17e-02 | |
| NFE2L3 | STM | Cervix | Healthy | SLC49A3,GABPB1,MIER1, etc. | 3.47e-01 |  |
| NFE2L3 | ASC | Colorectum | AD | FOSL1,DNAH12,HLA-DQB1, etc. | 2.25e-01 |  |
| NFE2L3 | STM | Colorectum | ADJ | BMP4,CNN2,TNS4, etc. | 7.55e-02 |  |
| NFE2L3 | INCAF | Esophagus | ADJ | CTSS,RP11-356I2.4,RBP5, etc. | 2.28e-02 |  |
| NFE2L3 | ALVMAC | Lung | Healthy | KCMF1,GBA,CISH, etc. | 3.75e-03 |  |
| NFE2L3 | cDC | Lung | Healthy | KCMF1,GBA,CISH, etc. | 2.00e-03 | |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 2 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NFE2L3 | SNV | Missense_Mutation | c.812N>T | p.Ser271Leu | p.S271L | Q9Y4A8 | protein_coding | deleterious(0) | probably_damaging(0.941) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| NFE2L3 | SNV | Missense_Mutation | c.1315N>G | p.His439Asp | p.H439D | Q9Y4A8 | protein_coding | tolerated(0.08) | benign(0.01) | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| NFE2L3 | SNV | Missense_Mutation | novel | c.1991T>C | p.Leu664Pro | p.L664P | Q9Y4A8 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
| NFE2L3 | SNV | Missense_Mutation | rs774380594 | c.827N>T | p.Ser276Leu | p.S276L | Q9Y4A8 | protein_coding | tolerated(0.23) | benign(0.007) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| NFE2L3 | SNV | Missense_Mutation | rs746360893 | c.1153N>A | p.Asp385Asn | p.D385N | Q9Y4A8 | protein_coding | deleterious(0.02) | benign(0.142) | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NFE2L3 | SNV | Missense_Mutation | novel | c.1609C>G | p.Arg537Gly | p.R537G | Q9Y4A8 | protein_coding | deleterious(0.01) | probably_damaging(0.968) | TCGA-B6-A400-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| NFE2L3 | SNV | Missense_Mutation | c.949G>A | p.Glu317Lys | p.E317K | Q9Y4A8 | protein_coding | deleterious(0) | possibly_damaging(0.868) | TCGA-C8-A26V-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | CR | |
| NFE2L3 | SNV | Missense_Mutation | c.1207T>A | p.Phe403Ile | p.F403I | Q9Y4A8 | protein_coding | deleterious(0) | benign(0.086) | TCGA-E9-A228-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| NFE2L3 | SNV | Missense_Mutation | novel | c.947N>G | p.His316Arg | p.H316R | Q9Y4A8 | protein_coding | tolerated(0.08) | benign(0.014) | TCGA-JL-A3YW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NFE2L3 | SNV | Missense_Mutation | rs144296822 | c.925N>G | p.Ile309Val | p.I309V | Q9Y4A8 | protein_coding | tolerated(0.21) | benign(0.006) | TCGA-S3-AA12-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |